Plasma concentrations of fibroblast growth factors 21 and 19 in patients with Cushing's syndrome

Physiological Research

Volumn 59, Issue 3, 2010, Pages 415-422

  Durovcova V ^a   Marek, J ^a   Hana V ^a   Matoulek, M ^a   Zikan V ^a   Haluzikova D ^a   Kavalkova P ^a   Lacinova Z ^a   Krsek M ^a   Haluzik M ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Fibroblast growth factor 19; Fibroblast growth factor 21; Hypercortisolism; Obesity

Indexed keywords

BIOLOGICAL MARKER; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 21; HYDROCORTISONE;

ADULT; ARTICLE; BLOOD; BODY MASS; CASE CONTROL STUDY; CUSHING SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MIDDLE AGED; OBESITY; PATHOPHYSIOLOGY; WAIST CIRCUMFERENCE;

ADIPOSITY; ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; CASE-CONTROL STUDIES; CUSHING SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; OBESITY; WAIST CIRCUMFERENCE;

EID: 77956281358     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. ANDERLOVÁ K, DOLEZALOVA R, HOUSOVA J, BOŠAcute; L, HALUZÍKOVÁ D, KŘEMEN J, ŠKRHA J, HALUZÍK M, Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. Physiol Res 56: 579-586, 2007.
2. BADMAN MK, PISSIOS P, KENNEDY AR, KOUKOS G, FLIER JS, MARATOS-FLIER E, Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5: 426-437, 2007.
3. BÖTTCHER RT, NIEHRS C, Fibroblast growth factor signaling during early vertebrate development. Endocr Rev 26: 63-77, 2005.
4. DOSTÁLová I, HALUZÍKová D, HALUZÍk M, Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus. Physiol Res 58: 1-7, 2009.
5. DOSTÁLová I, KAVÁLková P, HALUZÍKová D, LACINOVÁ Z, MRÁz M, PAPEŽOVÁ H, HALUZÍk M, Plasma concentrations of fibroblast growth factor 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 93: 3627-2632, 2008.
6. FU L, JOHN LM, ADAMS SH, YU XX, TOMLINSON E, RENZ M, WILLIAMS PM, SORIANO R, CORPUZ R, MOFFAT B, VANDLEN R, SIMMONS L, FOSTER J, STEPHAN JP, TSAI SP, STEWART TA. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145: 2594-2603, 2004.
7. GROSE R, DICKSON C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 16: 179-186, 2005.
8. HALUZÍk MM, ANDERLOVÁ K, DOLEŽALOVÁ R, ADAMÍKOVÁ A, HALUZÍKOVÁ D, HOUSOVÁ J, SVAČINA S, HALUZÍk M. Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment. Physiol Res 58: 93-99, 2009.
9. HAVEL PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 13: 51-59, 2002.
10. INAGAKI T, DUTCHAK P, ZHAO G, DING X, GAUTRON L, PARAMESWARA V, LI Y, GOETZ R, MOHAMMADI M, ESSER V, ELMQUIST JK, GERARD RD, BURGESS SC, HAMMER RE, MANGELSDORF DJ, KLIEWER SA. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab 5: 415-425, 2007.
11. JONES S. Mini-review: endocrine actions of fibroblast growth factor 19. Mol Pharm 5: 42-48, 2008.
12. KHARITONENKOV A, SHANAFELT AB. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. BioDrugs 22: 37-44, 2008.
13. KHARITONENKOV A, SHIYANOVA TL, KOESTER A, FORD AM, MICANOVIC R, GALBREATH EJ, SANDUSKY GE, HAMMOND LJ, MOYERS JS, OWENS RA, GROMADA J, Brozinick JT, HAWKINS ED, WROBLEWSKI VJ, LI DS, MEHRBOD F, JASKUNAS SR, SHANAFELT AB. FGF-21 as a novel metabolic regulator. J Clin Invest 115: 1627-1635, 2005.
14. KHARITONENKOV A, WROBLEWSKI VJ, KOESTER A, CHEN YF, CLUTINGER CK, TIGNO XT, HANSEN BC, SHANAFELD AB, ETGEN GJ, The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148: 774-781, 2007.
15. LUNDASEN T, GALMAN C, ANGELIN B, RUDLING M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 260: 530-536, 2006.
16. LUNDASEN T, HUNT MC, NILSSON LM, SANYAL S, ANGELIN B, ALEXSON SE, RUDLING M. PPARα is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 360: 437-440, 2007.
17. MRÁz M, BARTLOVá M, LACINOVá Z, MICHALSKÝ D, KASALICKÝ M, HALUZÍKOVÁ D, MATOULEK M, DOSTÁLOVÁ I, HUMENANSKÁ V, HALUZÍk M. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity; Clin Endocrinol 71: 369-375, 2009.
18. NISHIMURA T, NAKATAKE Y, KONISHI M, ITOH N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492: 203-206, 2000.
19. NISHIMURA T, UTSUNOMIYA Y, HOSHIKAWA M, OHUCHI H, ITOH N. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta 1444: 148-151, 1999.
20. PRESTA M, DELL'ERA P, MITOLA S, MORONI E, RONCA R, RUSNATI M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16: 159-178, 2005.
21. TOMLINSON E, FU L, JOHN L, HULTGREN B, HUANG X, RENZ M, STEPHAN JP, TSAI SP, POWELL-BRAXTON L, FRENCH D, STEWART TA. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143: 1741-1747, 2002.
22. WEIR JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol Lond 109: 1-9, 1949.
23. WENTE W, EFANOV AM, BRENNER M, KHARITONENKOV A, KOESTER A, SANDUSKY GE, SEWING S, TREINIES I, ZITZER H, GROMADA J. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55: 2470-2478, 2006.
24. XIE MH, HOLCOMB I, DEUEL B, DOWD P, HUANG A, VAGTS A, FOSTER J, LIANG J, BRUSH J, GU Q, HILLAN K, DOGGARD A, GURNEY AL. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 11: 729-735, 1999.
25. ZHANG X, YEUNG DC, KARPISEK M, STEJSKAL D, ZHOU Z, LIU F, WONG RLC, CHOW WS, TSO AWK, LAM KSL, XU A. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57: 1246-1253, 2008.